SCHEMBL5550169

SCHEMBL5550169

COC(=O)c1cc2c(Br)cnc(N)c2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 2/20 0.43
CCNC P24863 2/20 0.42
CDK8 P49336 2/20 0.42
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
CSNK2A1 P68400 2/20 0.42
KDR P35968 1/20 0.42
MAPK1 P28482 1/20 0.40
MAP2K1 Q02750 1/20 0.40
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38
ICAM1 P05362 1/20 0.37
SELE P16581 1/20 0.37
VCAM1 P19320 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16650594 0.84 CSNK2A2 (0.43) CCNCCDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL30530680 0.83 CCNC (0.43) CCNCCDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL5554833 0.83 CCNC (0.43) CCNCCDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL15203667 0.75 CSNK2A2 (0.49) CCNCCDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL5550771 0.74 MAP3K8 (0.81) MAP3K8CDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL5550639 0.74 ALDH1A1 (0.39) CCNCCDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL5553836 0.73 MAP3K8 (0.45) MAP3K8CSNK2A2CSNK2BCSNK2A1KDR
SCHEMBL5550172 0.73 MAP3K8 (0.53) MAP3K8CDK8CSNK2A2CSNK2BCSNK2A1
SCHEMBL29831616 0.72 ICAM1 (0.56) MAP3K8CCNCCDK8CDK9CSNK2A2
SCHEMBL5550652 0.72 ICAM1 (0.56) MAP3K8CCNCCDK8CDK9CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 MAP3K8 13/4885CCNC 981/4885CDK8 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.